Northwest Biotherapeutics Stock Forecast

Sell candidate since Jun 24, 2026 Gain 1.53%

The Northwest Biotherapeutics stock price gained 3.78% on the last trading day (Friday, 26th Jun 2026), rising from $0.185 to $0.192. During the last trading day the stock fluctuated 5.59% from a day low at $0.186 to a day high of $0.197. The price has fallen in 6 of the last 10 days but is still up by 2.64% over the past 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 441 thousand more shares were traded than the day before. In total, 2 million shares were bought and sold for approximately $357.78 thousand.

The stock is at the lower part of a very wide and horizontal trend in the short term, and normally this may pose a good buying opportunity, though a breakdown through the bottom trend line at $0.185 will give a strong sell signal and a trend shift may be expected. Given the current horizontal trend, you can expect Northwest Biotherapeutics stock with a 90% probability to be traded between $0.184 and $0.262 at the end of this 3-month period. A break of a horizontal trend is often followed by a large increase in the volume, and stocks seldom manage to go directly from the bottom of a trend up to the top. Stocks turning up in the middle of a horizontal trend are therefore considered to be potential runners.

NWBO Signals & Forecast

A buy signal was issued from a pivot bottom point on Thursday, June 25, 2026, and so far it has risen 3.78%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Northwest Biotherapeutics has increased volume and follows the last lift in the price. This is considered to be a technical positive sign as volume should follow the price-formation. Higher liquidity also reduces the general risk. Some negative signals were issued as well, and these may have some influence on the near short-term development. The Northwest Biotherapeutics stock holds a buy signal from the short-term Moving Average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term Moving Average at $0.215. On a fall, the stock will find some support from the short-term average at $0.190. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal.

Support, Risk & Stop-loss for Northwest Biotherapeutics stock

Northwest Biotherapeutics finds support from accumulated volume at $0.192 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.0104 between high and low, or 5.59%. For the last week, the stock has had daily average volatility of 8.87%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (NWBO) For The Upcoming Trading Day Of Monday 29th

For the upcoming trading day on Monday, 29th we expect Northwest Biotherapeutics to open at $0.192, and during the day (based on 14 day Average True Range), to move between $0.184 and $0.200, which gives a possible trading interval of +/-$0.0157 (+/-8.54%) up or down from last closing price. If Northwest Biotherapeutics takes out the full calculated possible swing range there will be an estimated 8.54% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $0.192 (0.18%) than the resistance at $0.195 (1.46%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is Northwest Biotherapeutics stock A Buy?

Northwest Biotherapeutics holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.

Current score: -1.742 Sell Candidate Unchanged

Predicted Fair Opening Price

Predicted fair opening price on June 29, 2026 - $0.192 ( 0.243%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker*
*Your capital is at risk